Opexa Therapeutics, Inc. (NASDAQ:OPXA) is a publically traded biotechnology company developing a personalized immunotherapy with the potential to treat major illnesses, including multiple sclerosis (MS) as well as other autoimmune diseases such as Neuromyelitis Optica (NMO). These therapies are based on Opexa’s proprietary T-cell technology, ImmPath®. The Company’s leading therapy candidate, Tcelna®, is a personalized T-cell immunotherapy that is in a Phase IIb clinical development program (the Abili-T trial) for the treatment of Secondary Progressive MS.
Opexa’s mission is to lead the field of Precision Immunotherapy™ by aligning the interests of patients, employees and shareholders.
Opexa's facility is located 30 miles North of Houston in The Woodlands, Texas and includes its cGMP facility, research laboratories and corporate offices.